Rafael Pharmaceuticals holds great pride in its mission to help heal patients with hard to treat cancers. Our people, our passion and our collective expertise in the field of precision medicine and clinical development define our company.
We’ve made a lot of progress, not only towards our goal of commercializing Rafael’s robustly innovative drug pipeline, but also in making key hires and creating advisory boards to strengthen Rafael’s foundation.
Rafael’s lead metabolic cancer drug, CPI-613® (devimistat), has achieved multiple and lasting remissions from some of the most intractable forms of cancer. We’ve presented promising data from our clinical trials at prestigious biotech/medical conferences. And while our focus is pancreatic cancer and acute myeloid leukemia (AML), we are also conducting clinical trials of CPI-613® (devimistat) in patients with MDS (myelodysplastic syndromes), Burkitt’s and Peripheral T-Cell lymphomas.
Strengthening the Rafael Foundation
We are only as strong as our people, drive and ingenuity. And we know it takes the best of the best in order to usher in a new paradigm in anticancer therapy. That is why we’ve hired and added board members, scientific advisors, and medical advisors who are all drawn from the highest echelons of the scientific and biotechnology community. Their willingness to tie their renowned reputations to our company speaks volumes about the immense potential of Rafael’s innovative therapies.
Rafael is the biblical angel of healing. In fact, the literal interpretation of Rafael is “God heals”. At Rafael Pharmaceuticals, we take our name as our mission and are developing breakthrough drugs that we believe will change how oncologists practice medicine.